Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EXS21546 for · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| EXS21546 Powder for Oral Suspension | EXPERIMENTAL | EXS21546 Powder for Oral Suspension |
| Placebo | PLACEBO_COMPARATOR | Placebo Powder for Oral Suspension |
| EXS21546 Granule in Capsule | EXPERIMENTAL | EXS21546 Granule in Capsule |
| Name | Type | Description |
|---|---|---|
| EXS21546 Powder for Oral Suspension | DRUG | EXS21546 Powder for Oral Suspension |
| EXS21546 Granule in Capsule | DRUG | EXS21546 Granule in Capsule |
| Midazolam | OTHER | Interaction |
| Food Effect | OTHER | Fed/Fasted |
| Placebo Powder for Oral Suspension | OTHER | Placebo Powder for Oral Suspension |
Inclusion Criteria: * BMI 18.0 to 30.0 kg/m2 * Weight ≥60 kg * Must adhere to contraception requirements Exclusion Criteria: * Subjects who have received any IMP in a clinical research study within the 90 days prior to Day 1 * Subjects who have previously been administered IMP in this study. * Ev...
EXS21546 is an investigational small molecule being developed for oncology. It is being studied for its safety, tolerability, pharmacokinetics, and pharmacodynamics in a Phase 1 clinical trial. The drug is not approved and remains in clinical development.
EXS21546 is being developed by Recursion Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker RXRX. The company is conducting clinical research on this investigational oncology small molecule.
EXS21546 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It has not been approved by regulatory authorities and is still undergoing clinical evaluation for oncology.
EXS21546 has one completed Phase 1 clinical trial, registered as NCT04727138. The study was a 3-part trial assessing safety, tolerability, pharmacokinetics, and pharmacodynamics in oncology, enrolling 64 participants in the United Kingdom, including healthy volunteers.
No alternative names for EXS21546 have been identified. The drug is referred to solely as EXS21546 in clinical trial records and development documentation. It is a distinct investigational small molecule being developed by Recursion Pharmaceuticals.